Relmada Therapeutics, a clinical-stage biotech company, will announce its financial results for the third quarter ending September 30, 2026, on November 12, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and recent business developments. Relmada is focused on developing therapies for oncology and central nervous system disorders, with lead candidates NDV-01 and sepranolone progressing in clinical trials. Investors can access the webcast live or via replay on the company's website.
Relmada Therapeutics plans to report its Q3 2026 financial results on November 12, 2026. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: out of 150 priced US health-sector stocks, 74 rose and 69 fell. Notable movers include NUVB at USD 4.81 with a 1-day change of +4.79%, ACB at USD 4.40 with +4.27%, and TVTX at USD 47.30 with -3.98%.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
